Fig. 2. Co-administration of unlabeled antibody reduced muscle uptake while maintained tumor uptake.
a Muscle antibody uptake (%ID kg−1: percent injected dose per kilogram) decreased with increasing total monoclonal antibody (mAb) dose (owing to loading dose (LD)). b, c. Tumor and skin uptake (%ID kg−1) as normalized by muscle uptake (%ID kg−1) were significantly higher in the loading dose group than that in the non-loading dose group, suggesting that tumor and skin were not fully saturated within the total antibody dose range of 0.3 mg kg−1 to 2.6 mg kg−1. d When tumor uptake was normalized by skin uptake, there was no significant differences between groups. The number of independent patient samples available in b: n = 9 (LD), n = 11 (non-LD); c n = 8 (LD), n = 9 (non-LD); d n = 8 (LD), n = 10 (non-LD). p value = 0.010 b, 0.046 c. Mann–Whitney U test (two-tailed) were used for comparison in b–d. Graphs plotted mean with standard deviation. (*p < 0.05. **p < 0.01, ns: p > 0.05).